Cargando…

Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance

SIMPLE SUMMARY: Immunotherapies such as anti-PD-1/PD-L1 have garnered increasing importance in cancer therapy, leading to substantial improvements in patient care and survival. However, a certain proportion of patients present tumors that resist these treatments. Exosomes, small vesicles secreted by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vautrot, Valentin, Bentayeb, Hafidha, Causse, Sébastien, Garrido, Carmen, Gobbo, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467727/ https://www.ncbi.nlm.nih.gov/pubmed/34572764 http://dx.doi.org/10.3390/cancers13184537

Ejemplares similares

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
por: Cordonnier, Marine, et al.
Publicado: (2020)

Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer
por: Vautrot, Valentin, et al.
Publicado: (2019)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
por: Chen, Gang, et al.
Publicado: (2018)

The role of exosomal PD-L1 in tumor progression and immunotherapy
por: Xie, Feiting, et al.
Publicado: (2019)

Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy
por: Yin, Enzhi, et al.
Publicado: (2023)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
por: Li, Chuling, et al.
Publicado: (2019)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Yin, Zi, et al.
Publicado: (2021)

Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
por: De Almeida, Steven, et al.
Publicado: (2020)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
por: Shimada, Yoshihisa, et al.
Publicado: (2021)

Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
por: Ayala-Mar, Sergio, et al.
Publicado: (2021)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
por: Zalba, Sara, et al.
Publicado: (2020)

Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis
por: Yu, Jialiang, et al.
Publicado: (2019)

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
por: Su, Dandan, et al.
Publicado: (2019)

The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
por: Tang, Yanyan, et al.
Publicado: (2020)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
por: Poggio, Mauro, et al.
Publicado: (2019)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling
por: Carter, Rachel, et al.
Publicado: (2023)

Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2023)

β-Catenin regulates tumor-derived PD-L1
por: Han, Chuanhui, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rircpvm6o0dnvamt9o89bh0cde